Likewise, small molecule activators of neurotrophic factor receptors, such as the Met receptor agonist K1K1 (Vallarola et al., 2020), or the non-peptide Ret modulator BT44 (Viisanen et al., 2020), have been developed for the treatment of neurodegenerative diseases. Here, RET is linked to neurodegenerative disease.